More positive data for first-in-class asset with blockbuster potential

6 September 2021
astrazeneca_big

At the annual meeting of the European Respiratory Society (ERS), British pharma major AstraZeneca (LSE: AZN) presented new data from the Phase III NAVIGATOR trial of asthma antibody tezepelumab.

Developed in partnership with California’s Amgen (Nasdaq: AMGN), the biologic was shown to reduce exacerbations and nasal symptoms, as well as improve lung function.

The one-year data relate to an exploratory endpoint in the trial, which showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate (AAER) in people with nasal polyps and 52% in those without, compared to placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology